Skip to main content
Addgene

Enter a sequence to perform a BLAST-based search of Addgene plasmid sequence databases.

In Category

Filter By

We narrowed to 155 results for: INA

Showing: 141 - 155 of 155 results

  1. pSMAL-CellTag-V2 (Concentrated Lentiviral Prep)

    Viral Prep
    #115644-LVC
    Purpose
    Ready-to-use Concentrated Lentiviral Prep particles produced from pSMAL-CellTag-V2 (#115644). In addition to the viral particles, you will also receive purified pSMAL-CellTag-V2 plasmid DNA. Ready-to-use lentiviral particles carrying version 2 of the CellTag barcoding library to combinatorially index cells for single-cell analysis of clonal dynamics.
    Depositor
    Samantha Morris
    Article
    Biddy et al Nature. 2018 Dec;564(7735):219-224. doi:
    Promoter
    Minimal CMV
    Tags
    EGFP
    Available since
    Oct. 29, 2019
    Availability
    Academic Institutions and Nonprofits only

  2. pAAV-EF1a-Flpo (AAV1)

    Viral Prep
    #55637-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    None
    Available since
    July 8, 2019
    Availability
    Academic Institutions and Nonprofits only

  3. pAAV-EF1a-Cre (AAV11)

    Viral Prep
    #55636-AAV11
    Purpose
    Ready-to-use AAV11 particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    None
    Available since
    July 16, 2025
    Availability
    Academic Institutions and Nonprofits only

  4. pAAV-EF1a-Flp-DOG-NW (AAV1)

    Viral Prep
    #75469-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-EF1a-Flp-DOG-NW (#75469). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flp-DOG-NW plasmid DNA. EF1a-driven expression of Flp recombinase dependent on GFP (Flp-DOG); to be coinjected with GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Connie Cepko
    Article
    Tang et al Elife. 2016 May 20;5. pii: e15312. doi:
    Promoter
    EF-1a
    Tags
    None
    Available since
    Feb. 19, 2020
    Availability
    Academic Institutions and Nonprofits only

  5. pAAV-EF1a-Flpo (AAV2)

    Viral Prep
    #55637-AAV2
    Purpose
    Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    None
    Available since
    March 18, 2024
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (AAV1)

    Viral Prep
    #75470-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (#75470). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, Flp recombinase-dependent expression of channelrhodopsin H134R mutant fused to mCherry. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Connie Cepko
    Article
    Tang et al Elife. 2016 May 20;5. pii: e15312. doi:
    Promoter
    CAG
    Tags
    mCherry
    Available since
    March 2, 2020
    Availability
    Academic Institutions and Nonprofits only

  7. pAAV-EF1a-Cre (AAV Retrograde)

    Viral Prep
    #55636-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    None
    Available since
    Nov. 12, 2020
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV-EF1a-Flpo (AAV Retrograde)

    Viral Prep
    #55637-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    None
    Available since
    April 2, 2019
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV-EF1a-mCherry-IRES-Flpo (AAV1)

    Viral Prep
    #55634-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a and Ef1a/IRES
    Tags
    mCherry
    Available since
    May 31, 2019
    Availability
    Academic Institutions and Nonprofits only

  10. pAAV-Ef1a-Con/Foff 2.0-BFP (AAV8)

    Viral Prep
    #137130-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    BFP (Cre-dependent)
    Available since
    March 19, 2021
    Availability
    Academic Institutions and Nonprofits only

  11. pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (AAV8)

    Viral Prep
    #137163-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    nEF
    Tags
    EYFP (Cre-dependent)
    Available since
    Nov. 23, 2020
    Availability
    Academic Institutions and Nonprofits only

  12. pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (AAV8)

    Viral Prep
    #137143-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    nEF
    Tags
    mCherry (Cre-dependent)
    Available since
    Feb. 25, 2021
    Availability
    Academic Institutions and Nonprofits only

  13. pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (AAV8)

    Viral Prep
    #183519-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do
    Promoter
    CaMKII
    Tags
    None
    Available since
    Dec. 18, 2024
    Availability
    Academic Institutions and Nonprofits only

  14. pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (AAV1)

    Viral Prep
    #105322-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.
    Depositor
    GENIE Project, Douglas Kim
    Article
    Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi
    Promoter
    Syn
    Tags
    None
    Available since
    June 13, 2019
    Availability
    Academic Institutions and Nonprofits only

  15. pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (AAV1)

    Viral Prep
    #105321-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.
    Depositor
    GENIE Project, Douglas Kim
    Article
    Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi
    Promoter
    Syn
    Tags
    None
    Available since
    July 12, 2019
    Availability
    Academic Institutions and Nonprofits only
Showing: 141 - 155 of 155 results